載入中
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
前收盤價
US$0.9163
−US$0.0314 · -3.31%
盤中時間採用ET。市場資料可能有所延遲。
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
日內區間
目前US$0.9163
52週區間
目前US$0.9163
盤中時間採用ET。市場資料可能有所延遲。
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
日內區間
目前US$0.9163
52週區間
目前US$0.9163
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 2566.29萬 USD | 4822.48萬 USD | 2945.87萬 USD | 4730.61萬 USD | 4493.65萬 USD |
| 銷售、一般及管理費用 | 960.24萬 USD | 1189.22萬 USD | 1333.54萬 USD | 1537.39萬 USD | 1128.3萬 USD |
| 營業費用 | 3526.52萬 USD | 6011.7萬 USD | 4279.41萬 USD | 6268萬 USD | 5621.95萬 USD |
| 利息收入 | 332.39萬 USD | 619.18萬 USD | 732.3萬 USD | 234.94萬 USD | 18.54萬 USD |
| 利息支出 | 190.53萬 USD | 192.62萬 USD | 207.1萬 USD | 169.41萬 USD | 174.21萬 USD |
| 折舊和攤銷 | 25.2萬 USD | 24.96萬 USD | 26.28萬 USD | 25.87萬 USD | 26.42萬 USD |
| 營業利益 | −3526.52萬 USD | −6011.7萬 USD | −4279.41萬 USD | −6268萬 USD | −5621.95萬 USD |
| 淨利 | −3384.67萬 USD | −5585.14萬 USD | −3754.25萬 USD | −6202.46萬 USD | −5777.63萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI264.1萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF84.9萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Health Care ETFVHT24.79萬0.00%220億 USD0.09%US$319.01+1.64%
iShares Micro-Cap ETFIWC17.77萬0.01%13.17億 USD0.60%US$183+0.11%
Invesco RAFI US 1500 Small-Mid ETFPRFZ9.42萬0.00%26.7億 USD0.36%US$53.16+0.64%
Invesco NASDAQ Future Gen 200 ETFQQQS7.42萬0.33%2275.83萬 USD0.20%US$42.145+1.39%
Dimensional - US Small Cap ETFDFAS3.78萬0.00%338.69億 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZInvesco NASDAQ Future Gen 200 ETFQQQSDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
